marked.bio

KRAS G12D inhibitor · small molecule

TSN1611

1 active trials, targeting KRAS G12D. Not approved for any biomarker on marked.bio yet.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
KRAS G12D 1 1 Phase 1/2

Sponsors

Industry sponsors leading active biomarker-selected trials of TSN1611.

  1. Tyligand Pharmaceuticals 1

Trials

1 of 1 trials shown

  1. A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

    Recruiting Phase 1/2 Tyligand Pharmaceuticals Started 2024Primary completion 2026-10 NCT06385925

    TSN1611paclitaxeloxaliplatinfluorouracilleucovorin

    …logically or cytologically confirmed locally advanced or metastatic solid tumor harboring KRAS G12D mutation

    KRAS G12DMalignant Neoplasm